NEW YORK (TheStreet) -- Shares of Conatus Pharmaceuticals  (CNAT) - Get Conatus Pharmaceuticals Inc. Report fell 11.09% to $6.05 in afternoon trading Thursday after the company priced an underwritten public offering of its common stock.

The company priced 3.5 million shares at $5.75 a share for gross proceeds of approximately $20.1 million. The offering contains a 30-day option for underwriters to purchase up to an additional 525,000 shares.

Conatus expects the offering to close on or about April 8.

The company said in a statement it plans to use the proceeds to "fund clinical development of emricasan, including preparation for registration trials, and for working capital and other general corporate purposes."

TheStreet Recommends

Conatus is a biotechnology company focused on the development and commercialization of new medicines to treat liver disease.

More than 2.9 million shares had changed hands as of 2:04 p.m., compared to the daily average volume of 971,645.

CNAT data by YCharts

Image placeholder title